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471 adults comprising the ITT population (234 MXF,
237 AC), MXF treatment was statistically equivalent to
AC at the TOC visit (85.2% vs 81.8%; 95%CI 
6%,13%). Per-protocol analysis also confirmed statisti-
cal equivalence between MXF and AC (86.5% vs 83.6%;
95%CI  7%,13%). Rates of relapse were similar for
the ITT (4% MXF, 5% AC) and the per-protocol (4%
both) populations. The frequency of drug-related adverse
events were similar between MXF (30%) and AC (25%)
and were primarily gastrointestinal-related: nausea (11%
MXF, 5% AC) and diarrhea (3% MXF, 10% AC). At
the TOC visit, significantly more MXF-treated patients
(n  47; 24%) in the ITT population than AC-treated
patients (n  28; 14%) reported symptomatic improve-
ment by day 3 (p  0.02). No differences existed in terms
of lost work hours or time to return to normal activities
between treatment groups. CONCLUSIONS: In this pri-
mary care clinical trial, once-daily MXF was as effective
and safe as twice-daily AC in the treatment of AMS. In
some patients, MXF was associated with more rapid
symptomatic relief, which has potential clinical and so-
cioeconomic implications.
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OBJECTIVES: To compare utilities for HIV/AIDS health
states derived from community-based preferences with
those derived from patients, and to examine the implica-
tions of differences for a cost-effectiveness analysis of
early versus deferred treatment of HIV patients present-
ing with CD4 cell counts of 500/L. METHODS: We
used data from the HIV Cost and Services Utilization
Study (HCSUS), a probability sample of 2,864 HIV-
infected adults receiving care in the United States in 1996,
to derive utilities for HIV/AIDS health states. Commu-
nity-based utilities were calculated from the SF-6D re-
sponses in the HCSUS survey using algorithms derived by
Brazier et al. Patient utilities were calculated from patient
self-assessments using a rating scale transformation de-
rived by Torrance et al. We used a computer-based state-
transition simulation model of HIV disease to conduct
cost-effectiveness analyses using both community and pa-
tient utilities. RESULTS: Patient utilities were signifi-
cantly higher (by 4% to 9%, p  0.001) than community
utilities for all disease stages: for asymptomatic HIV pa-
tients 0.970 (0.963–0.977) vs. 0.937 (0.926–0.949); for
symptomatic HIV patients 0.910 (0.902–0.919) vs. 0.841
(0.826–0.855); and for patients with a history of an
AIDS-defining condition 0.845 (0.832–0.858) vs. 0.778
(0.761–0.795). The cost-effectiveness ratio of early ther-
apy (initiated at 500 CD4 cells/L) versus deferred ther-
apy (initiated at 200 CD4 cells/L) was $20,100/QALY
using community utilities and $18,400/QALY using pa-
tient utilities. In a sensitivity analysis, when we assumed a
20% reduction in quality of life due to side effects during
early therapy but not during deferred therapy, the cost-
effectiveness ratio of early versus deferred therapy was
$50,900/QALY using community utilities and $46,300/
QALY using patient utilities. CONCLUSIONS: There
are differences between community and patient utilities
for HIV/AIDS health states. The impact of these differ-
ences on HIV/AIDS cost-effectiveness results should be
considered when treatment side effects are important.
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OBJECTIVE: Among sepsis survivors, during recovery
and thereafter, it is not established if patients resume or
improve their quality of life. The study objective was to
assess change in health status among sepsis survivors
over a 6-month period. METHODS: This was a prospec-
tive, multicenter, cohort study involving 701 patients
with severe sepsis of presumed infectious origin from 53
hospitals. Patients’ health status was assessed at day 30,
60, 90 and180 using EuroQoL-5D and a visual analog
scale. Instruments were completed by the patient while in
hospital and follow-up assessments were performed by
telephone interview. RESULTS: For this interim analysis,
93 patients had completed health state information for
day 30, 60, 90, and 180. Mean (SD) age was 60  17
years and 48% were female. The number of patients re-
maining in the hospital decreased from 56% at day 30 to
7%, thereafter. The average utility score/VAS score at
each time point was: 0.53/0.61 (day 30), 0.62/0.68 (day
60), 0.68/0.71 (day 90), 0.69 (p  0.0001)/0.72 (day
180). Based on patients’ subjective assessment of their
health status during the last 12 months, 60% had im-
proved or maintained their health. The improvement in
utility scores was influenced primarily by changes in mo-
bility, self-care, and usual activities. Pain and anxiety ap-
peared to have a minimal influence on overall improve-
ment in health status. At day 30, 28% of the patients
reported no problems in walking, compared to 58% at
day 180. Likewise, 48% and 26% of patients reported no
problems with self-care and performing usual activities at
day 30, respectively, and 67% (self-care) and 47% (usual
activities) at day 180. CONCLUSION: Sepsis survivors
experienced a continual improvement towards popula-
tion-based normal levels in their health utility scores over
a 6-month period. Improvements in physical activity,
self-care and usual activities were predominantly associ-
ated with improved health utility.
